Literature DB >> 27498857

Association between GSTM1, GSTT1, and GSTP1 variants and the risk of end stage renal disease.

Hamid Nomani1,2, Lida Hagh-Nazari1,2, Ali Aidy1,3, Asad Vaisi-Raygani1,2, Amir Kiani1,2, Zohreh Rahimi4, Fariborz Bahrehmand1,2, Ebrahim Shakiba1,2, Hamid Reza Mozaffari5, Heidar Tavilani6, Tayebeh Pourmotabbed7.   

Abstract

INTRODUCTION: There are some evidences indicating DNA damage by oxidant and mutant agents has an essential role in the chronic renal failure and end stage renal disease (ESRD). To investigate the possible association of GSTs variants with ESRD, we investigated the frequency of GST- T1, M1, and P1 genotypes, and the level of malondialdehyde (MDA) in patients with ESRD.
MATERIALS AND METHODS: The present case-control study consisted of 136 ESRD patients treated with maintenance hemodialysis and 137 gender- and age-matched, unrelated healthy controls from the population of west of Iran. The GST- T1, M1, and P1 genotypes were determined in all individuals using multiplex-PCR and PCR-RFLP. The level of MDA was measured by high-performance liquid chromatography (HPLC).
RESULTS: We found that GSTM1 and GSTT1 null genotypes (GSTT1-/GSTM1-) increased the risk of ESRD by 1.8 times (p < 0.001) and the increased risk of ESRD for GSTM-null (T1+-M1-) genotype was 3.04 times (p = 0.002). ESRD patients carriers the GST (GSTM1-null + GSTT1-null + GST-null) genotypes compared to GST normal genotype increased the risk of ESRD by 3.3 (p < 0.001) times. ESRD patients carriers of GST-null, GSTM1-null, and GSTT1-null genotypes had greater MDA concentration compared with the same genotypes of control subjects. Our results indicated that the GST-null allele (GSTT1-null/GSTM1-null) is a risk factor for ESRD and carriers of this allele have high levels of MDA.
CONCLUSION: Our findings indicate that oxidative stress, impairment of the antioxidant system and abnormal lipid metabolism may play a role in the pathogenesis and progression of ESRD and its related complications. These data suggest that patients with ESRD are more susceptible to vascular diseases.

Entities:  

Keywords:  Glutathione s-transferase; end stage renal disease; hemodialysis; malondialdehyde; polymorphism

Mesh:

Substances:

Year:  2016        PMID: 27498857     DOI: 10.1080/0886022X.2016.1214054

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  8 in total

1.  Identification of dicarbonyl and L-xylulose reductase as a therapeutic target in human chronic kidney disease.

Authors:  Paul Perco; Wenjun Ju; Julia Kerschbaum; Johannes Leierer; Rajasree Menon; Catherine Zhu; Matthias Kretzler; Gert Mayer; Michael Rudnicki
Journal:  JCI Insight       Date:  2019-06-20

2.  Association of Polymorphisms in Antioxidant Enzyme-Encoding Genes with Diabetic Nephropathy in a Group of Saudi Arabian Patients with Type II Diabetes Mellitus.

Authors:  Fatma I Albeladi; Mostafa M Mostafa; Mohamed A Zayed; Hazem Atta
Journal:  Int J Gen Med       Date:  2022-07-01

3.  Pharmacogenomic analysis of a genetically distinct Indigenous population.

Authors:  Arvind Jaya Shankar; Sudhir Jadhao; Wendy Hoy; Simon J Foote; Hardip R Patel; Vinod Scaria; Brendan J McMorran; Shivashankar H Nagaraj
Journal:  Pharmacogenomics J       Date:  2021-11-25       Impact factor: 3.245

4.  The relationship between inflammatory factors, oxidative stress and DIO-1 concentration in patients with chronic renal failure accompanied with or without euthyroid sick syndrome.

Authors:  Shu-Lan Qin; Qi He; Ling Hu; Chun-Yan He; Li-Cheng Gao; Charlotte Aimee Young; Juan Chen; Cheng-Fang Jiang; Xiang-Feng Luo; Ying Zhou; Xia Sheng; Zhi-Hong Li; Mei-Ling Chen; Gaosi Xu
Journal:  J Int Med Res       Date:  2018-08-28       Impact factor: 1.671

5.  Genetic variants of glutathione S-transferase and the risk of acute myeloid leukemia in a Saudi population.

Authors:  Abdullah Farasani
Journal:  Saudi J Biol Sci       Date:  2018-12-21       Impact factor: 4.219

6.  GSTT1 null and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients.

Authors:  Shahid M Baba; Arshad A Pandith; Zafar A Shah; Sajad A Geelani; Javid R Bhat; Ayaz Gul; Sameer A Guru; Hamed A El-Serehy; Abid M Koul; Sheikh Mansoor
Journal:  Front Oncol       Date:  2021-10-14       Impact factor: 6.244

7.  Sickle Cell Anemia Patients in Use of Hydroxyurea: Association between Polymorphisms in Genes Encoding Metabolizing Drug Enzymes and Laboratory Parameters.

Authors:  Sètondji Cocou Modeste Alexandre Yahouédéhou; Magda Oliveira Seixas Carvalho; Rodrigo Mota Oliveira; Rayra Pereira Santiago; Caroline Conceição da Guarda; Suellen Pinheiro Carvalho; Júnia Raquel Dutra Ferreira; Milena Magalhães Aleluia; Elisângela Vitória Adorno; Marilda de Souza Gonçalves
Journal:  Dis Markers       Date:  2018-01-28       Impact factor: 3.434

8.  Chemerin rs17173608 and vaspin rs2236242 gene variants on the risk of end stage renal disease (ESRD) and correlation with plasma malondialdehyde (MDA) level.

Authors:  Hamid Nomani; Hamid Khanmohamadian; Asad Vaisi-Raygani; Ebrahim Shakiba; Maryam Tanhapour; Zohreh Rahimi
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.